MiMedx Group

MiMedx Group was incorporated on February 28, 2008. Its initial assets consisted of our HydroFix® and CollaFixTM technology platforms. On January 5, 2011, the company acquired all of the outstanding equity interests in Surgical Biologics, LLC, and subsequently consolidated the corporate offices and operating facilities in Kennesaw, Georgia. This strategic acquisition brought together amnion tissue processing technology with MiMedx®'s experienced management team and extensive distribution network in order to position the company for market opportunities across multiple areas of medicine. Surgical Biologics developed allografts and other products processed from human amniotic membrane that can be used for a wide range of medical applications, including ocular surface repair, gum repair, wound care, nerve and tendon protection, spine surgery, burn treatment, and many other types of procedures that require the repair of a patient’s integumental (native) tissue.
Type
Public
HQ
Marietta, US
Size (employees)
690 (est)+26%
Website
mimedx.com
MiMedx Group is headquartered in Marietta, US

Key People at MiMedx Group

Parker H. Petit

Parker H. Petit

CEO & Chairman
Deborah Dean

Deborah Dean

Executive Vice President
William C. Taylor

William C. Taylor

President and Chief Operating Officer
Frank Burrows

Frank Burrows

Vice President of Corporate Strategy
Rebeccah J. C. Brown

Rebeccah J. C. Brown

Vice President of Product Development, Regulatory Affairs, and Quality Assurance

MiMedx Group Office Locations

MiMedx Group has an office in Marietta
Marietta, US (HQ)
1775 West Oak Commons Ct. Ne

MiMedx Group Metrics

MiMedx Group Financial Metrics

Revenue (2016)

$245 m

Revenue growth (2015-16), %

31%

Gross profit

$212.6 m

Gross profit margin (2016), %

87%

Net income (2016)

$12 m

Market capitalization (28-Apr-2017)

$1.4 b

Closing share price (28-Apr-2017)

$11.4

Cash (31-Dec-2016)

$34.4 m
MiMedx Group's current market capitalization is $1.4 b.
MiMedx Group's revenue was reported to be $245 m in FY, 2016 which is a 31% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$59.2 m$118.2 m$187.3 m$245 m

Revenue growth, %

100%58%31%

Cost of goods sold

$9.3 m$12.7 m$20.2 m$32.4 m

Gross profit

$49.9 m$105.6 m$167.1 m$212.6 m

Gross profit Margin, %

84%89%89%87%

EBIT

($2.6 m)$7.1 m$24.4 m$18.4 m

EBIT margin, %

(4%)6%13%8%

Interest income

($45.2 k)($48 k)($86 k)($339 k)

Pre tax profit

($4 m)$7.1 m$24.3 m$18.1 m

Net Income

($4.1 m)$6.2 m$29.4 m$12 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$44.1 m$46.6 m$28.5 m$34.4 m

Accounts Receivable

$16.1 m$26.7 m$53.8 m$67.2 m

Inventories

$1.5 m$3.6 m

Current Assets

$65.4 m$85.7 m$96.3 m$126.5 m

PP&E

$4.1 m$5.4 m$9.5 m$13.8 m

Goodwill

$4 m$4 m$4 m$20.2 m

Total Assets

$84.7 m$109.3 m$135.9 m$193.3 m

Accounts Payable

$2.5 m$3.7 m$6.6 m$11.4 m

Current Liabilities

$9.6 m$18.4 m$26.8 m$50.7 m

Additional Paid-in Capital

$147.3 m$162.4 m$163.1 m$161.3 m

Retained Earnings

($73.8 m)($67.6 m)($38.1 m)($26.2 m)

Total Equity

$73.6 m$89.3 m$108 m$133 m

Financial Leverage

1.2 x1.2 x1.3 x1.5 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($4.1 m)$6.2 m$29.4 m$12 m

Depreciation and Amortization

$1.1 m$928 k$933 k$2.1 m

Accounts Receivable

($8.4 m)($11 m)($27 m)($11 m)

Inventories

($858 k)($203 k)($2.3 m)($2.8 m)

Accounts Payable

$1.2 m$1.3 m$3.1 m($3.7 m)

Cash From Operating Activities

($285.5 k)$16.8 m$18.8 m$25.8 m

Cash From Investing Activities

($3 m)($12.2 m)($678 k)($11.7 m)

Cash From Financing Activities

$40.6 m($2.1 m)($36.2 m)($8.2 m)

Income Taxes Paid

$5.8 m

MiMedx Group Market Value History

MiMedx Group Online Presence

MiMedx Group Company Life

You may also be interested in